Should I buy or sell Marinus Pharmaceuticals stock right now?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last twelve months. There are currently 6 b...
What is Marinus Pharmaceuticals' stock price forecast for 2022?
6 brokerages have issued twelve-month price targets for Marinus Pharmaceuticals' shares. Their forecasts range from $22.00 to $50.00. On average, t...
How has Marinus Pharmaceuticals' stock performed in 2022?
Marinus Pharmaceuticals' stock was trading at $11.88 at the beginning of 2022. Since then, MRNS stock has decreased by 62.8% and is now trading at...
When is Marinus Pharmaceuticals' next earnings date?
Marinus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Tuesday, August 9th 2022. View our earnings forecast f...
How were Marinus Pharmaceuticals' earnings last quarter?
Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) released its earnings results on Monday, March, 21st. The biopharmaceutical company reported ($0.77) ea...
When did Marinus Pharmaceuticals' stock split? How did Marinus Pharmaceuticals' stock split work?
Marinus Pharmaceuticals shares reverse split on the morning of Wednesday, September 23rd 2020. The 1-4 reverse split was announced on Tuesday, Sept...
Who are Marinus Pharmaceuticals' key executives?
Marinus Pharmaceuticals' management team includes the following people: Dr. Scott N. Braunstein M.D. , CEO, Pres & Director (Age 59, Pay $869.03...
Who are some of Marinus Pharmaceuticals' key competitors?
Some companies that are related to Marinus Pharmaceuticals include Theravance Biopharma (TBPH) , Erasca (ERAS) , CTI BioPharma (CTIC) , Atea Ph...
What other stocks do shareholders of Marinus Pharmaceuticals own?
Based on aggregate information from My MarketBeat watchlists, some companies that other Marinus Pharmaceuticals investors own include Nordic Ameri...
About Marinus Pharmaceuticals
Marinus Pharmaceuticals (NASDAQ:MRNS) Frequently Asked Questions
Marinus Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the identification and development of neuropsychiatric therapeutics. Its clinical stage drug product candidate, ganaxolone, is a positive allosteric modulator being developed in three different dose forms: intravenous, capsule, and liquid.
Signals & Forecast
6 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Marinus Pharmaceuticals in the last year. There are currently 6 buy ratings for the stock.
Support, Risk & Stop-loss
The Marinus Pharmaceuticals stock holds buy signals from both short and long-term moving averages giving a positive forecast for the stock, but the stock has a general sell signal from the relation between the two signals where the long-term average is above the short-term average.
Is Marinus Pharmaceuticals stock A Buy?
On the downside, the stock finds support just below today's level from accumulated volume at $10.54 and $10.43. There is natural risk involved when a stock is testing a support level, since if this is broken, the stock then may fall to the next support level. In this case, Marinus Pharmaceuticals finds support just below today's level at $10.54.
Insiders are positive buying more shares than they are selling in Marinus Pharmaceuticals
Several short-term signals are positive, despite the stock being in a falling trend, we conclude that the current level may hold a buying opportunity as there is a fair chance for stock to perform well in the short-term.
About Marinus Pharmaceuticals
In the last 100 trades there were 8.89 million shares bought and 2.06 million shares sold. The last trade was done 5 days ago by Vitullo Nicole who bough 12.38 thousand shares. The large amount of stocks bought compared to stocks sold indicate that the insiders believe there is a potential good upside.
Golden Star Signal
Marinus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on developing and commercializing therapeutics to treat epilepsy and neuropsychiatric disorders.
Top Fintech Company
This unique signal uses moving averages and adds special requirements that convert the very good Golden Cross into a Golden Star. This signal is rare and, in most cases, gives substantial returns. From 10 000+ stocks usually only a few will trigger a Golden Star Signal per day!
What is Marinus Pharmaceuticals?
featured in The Global Fintech Index 2020 as the top Fintech company of the country.
What is Marinus' business?
It is focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy
Does market cap include convertible securities?
Marinus manages the business in one segment, which is the identification and development of neuropsychiatric therapeutics. The Company is developing ganaxolone for multiple epilepsy and other neuropsychiatric indications, including adjunctive, or add-on, therapy.
